Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

References

• World Health Organization. Global hepatitis report, 2017 Available from: http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1. Accessed 121, 2019.
   Google Scholar
• Ditah I, Ditah F, Devaki P, et al. The changing epidemiology of hepatitis C virus infection in the United States: national health and nutrition examination survey 2001 through 2010. J Hepatol. 2014;60:691–698. doi:10.1016/j.jhep.2013.11.01424291324
   PubMed Web of Science ®Google Scholar
• Edlin BR, Eckhardt BJ, Shu MA. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62:1353–1363. doi:10.1002/hep.2797826171595
   PubMed Web of Science ®Google Scholar
• Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2013;59(1):318–327. doi:10.1002/hep.26639
   Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves Vosevi for hepatitis C [press release]. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm567467.htm. Accessed 1 21, 2019.
   Google Scholar
• AASLD/IDSA HCV Guidelines. Recommendations for testing, managing, and treating hepatitis C. Available from: https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/HCVGuidance_May_24_2018b.pdf. Accessed 121, 2019.
   Google Scholar
• Wang LS, Dsouza LS, Jacobson IM. Hepatitis C- A clinical review. J Med Virol. 2016;88:1844–1855. doi:10.1002/jmv.2455427097298
   PubMed Web of Science ®Google Scholar
• Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat. 2012;19(7):449–464. doi:10.1111/j.1365-2893.2012.01617.x22676357
   PubMed Web of Science ®Google Scholar
• Vosevi^® [prescribing Information]. Foster City, CA: Gilead Sciences, Inc; 2017.
   Google Scholar
• European Medicines Agency. Vosevi EPAR summary for the public. https://www.ema.europa.eu/en/documents/overview/vosevi-epar-summary-public_en.pdf. Accessed 4 28, 2019
   Google Scholar
• Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134–2146. doi:10.1056/NEJMoa161351228564569
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 Weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153(1):113–122. doi:10.1053/j.gastro.2017.03.04728390869
   PubMed Web of Science ®Google Scholar
• Bourliere M, Gordon SC, Schiff ER, et al. Deferred treatment of sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. Lancet Gastroenterol Hepatol. 2018;3:559–565. doi:10.1016/S2468-1253(18)30118-329859740
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Cooper CL, Manns MP, et al. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. J Hepatol. 2018;69:1221–1230. doi:10.1016/j.jhep.2018.07.02330098373
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Gordon S, et al. Patient-reported outcomes following treatment of chronic hepatitis C virus infection with sofosbuvir and velpatasvir, with or without voxilaprevir. Clin Gastroenterol Hepatol. 2018;16(4):567–574. doi:10.1016/j.cgh.2017.11.02329155352
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Jacobson IM, et al. Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. Aliment Pharmacol Ther. 2018;47(2):259–267. doi:10.1111/apt.1442329181842
   PubMed Web of Science ®Google Scholar
• Cacoub P, Bourliere M, Asselah T, et al. French patients with hepatitis C treated with direct-acting antiviral combinations: the effect of patient-reported outcomes. Value Health. 2018;21(10):1218–1225. doi:10.1016/j.jval.2018.01.00630314623
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015;63:337–345. doi:10.1016/j.jhep.2015.03.01425795586
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients co-infected with hepatitis C virus and HIV: the impact on patient‐reported outcomes. J Infect Dis. 2015;212:367‐377. doi:10.1093/infdis/jiv005
   Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Nader F, et al. Patient‐reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir‐containing regimens. Hepatology. 2014;59:2161‐2169. doi:10.1002/hep.27161
   Web of Science ®Google Scholar
• Ruane P, Strasser SI, Gane EJ, et al. Sofosbuvir/velpatasvir/voxilaprevir for patients with HCV who previously received a sofosbuvir/velpatasvir-containing regimen: results from a retreatment study. J Viral Hepat. 2019;00:1–4.
   Google Scholar
• Rodriguez-Torres M, Glass S, Hill J. GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study. J Viral Hepat. 2016;23(8):614–622. doi:10.1111/jvh.1252726957110
   PubMed Web of Science ®Google Scholar
• Han B, Parhy B, Zhou E, et al. In vitro susceptibility of hepatitis C virus genotype 1 through 6 clinical isolates to the pangenotypic NS3/4A inhibitor voxilaprevir. J Clin Microbiol. 2019;57(4):e01844–18. doi:10.1128/JCM.01844-18
   Web of Science ®Google Scholar
• Pham LV, Jensen SB, Fahnøe U, et al. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape. J Hepatol. 2019;70(3):388–397. doi:10.1016/j.jhep.2018.10.03130395912
   PubMed Web of Science ®Google Scholar
• Wyles DL, Lawitz E, Cheinquer N, et al. Emergence and long-term persistence of NS3, NS5A, and NS5B resistance associated substitutions after treatment with direct-acting antivirals. Gastroenterology. 2018;54(6 Suppl1):S1104. doi:10.1016/S0016-5085(18)33672-2
   Google Scholar
• Gilead Sciences. Safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir fixed-dose combination for 12 weeks in adults who participated in a prior gilead-sponsored HCV treatment study - study results. NLM Identifier: NCT3118843 Available from: https://clinicaltrials.gov/ct2/show/results/NCT3118843. Accessed 428, 2019.
   Google Scholar
• Food and Drug Administration. FDA adverse event reporting system (FAERS) public dashboard. Available from: https://www.fda.gov/drugs/fda-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed 322, 2019.
   Google Scholar
• University of Liverpool. HEP drug interactions. Available from: http://hep-druginteractions.org/ . Accessed 121, 2019.
   Google Scholar
• Piecha F, Gänßler J-M, Jordan S, et al. Transjugular intrahepatic portosystemic shunt: a possible risk factor for direct‐acting antiviral treatment failure in patients with hepatitis C? Hepatol Commun. 2019;3(5):614–619. doi:10.1002/hep4.133731061950
   PubMed Web of Science ®Google Scholar
• Cardona‐Gonzalez MG, Goldman JD, Narayan L, Brainard DM, Kowdley KV. Sofosbuvir, velpatasvir, and voxilaprevir for treatment of recurrent hepatitis c virus infection after liver transplantation. Hepatol Commun. 2018;2(12):1446–1450. doi:10.1002/hep4.128030556034
   PubMed Web of Science ®Google Scholar
• Grebely J, Feld JJ, Wyles D, et al. Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: an analysis of phase 3 studies. Open Forum Infect Dis. 2018;5:2. doi:10.1093/ofid/ofy001
   Web of Science ®Google Scholar
• European AIDS Clinical Society. Guidelines Version 9.1 October 2018. Available from: http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf. Accessed 121, 2019.
   Google Scholar
• Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed, 428, 2019.
   Google Scholar
• Bacon B, Curry MP, Flamm SL, et al. Access to and utilization of sofosbuvir/velpatasvir/voxilaprevir in care of chronic hepatitis c patients; data from the trio network. Gastroenterology. 2018;54(6 Suppl1):S1192–S1193. doi:10.1016/S0016-5085(18)33942-8
   Google Scholar